What is the 13F Pro Quality Score for VRDN?

13F Pro ranks Viridian Therapeutics, Inc.\DE (VRDN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VRDN's current score at https://13fpro.ai/research/VRDN (free sign-up required for the full ranking).

Which hedge funds own the most VRDN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VRDN include FMR, BlackRock,, Bellevue Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VRDN as soon as new 13F filings post.

Where does 13F Pro source VRDN data?

All Viridian Therapeutics, Inc.\DE fundamentals and ownership data come directly from SEC EDGAR. Viridian Therapeutics, Inc.\DE files with the SEC under CIK 1590750. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VRDN in?

Viridian Therapeutics, Inc.\DE (VRDN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VRDN research updated on 13F Pro?

VRDN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Viridian Therapeutics, Inc.\DE(VRDN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1590750 VRDN stock profile & AI dashboard →

13F Pro Quality Score

30.5/100

Rank #2,352 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.9/100

Profitability

3.6/100

Balance Sheet

5.7/100

Earnings Quality

30.0/100

Free Cash Flow

3.1/100

Institutional Flow

92.9/100

Revenue Scale

14.1/100

Dilution Risk

4.3/100

VRDN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Viridian Therapeutics, Inc.\DE (VRDN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRDN at 30.5/100 on a 32-signal composite quality model, placing it at rank #2,352 of 2,879 stocks — the bottom half of the AI-ranked universe. VRDN scores in the top quartile across revenue growth (99.9), institutional flow (92.9). Areas of concern include free cash flow (3.1) and profitability (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Viridian Therapeutics, Inc.\DE reports quarterly revenue of $141.0K, net income of $-104.9M, free cash flow of $-119.7M. Top institutional holders of VRDN by reported 13-F value include FMR, BlackRock,, Bellevue Group AG, based on the most recent SEC filings. VRDN trades on the Nasdaq exchange and files with the SEC under CIK 1590750. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viridian Therapeutics, Inc.\DE directly from SEC EDGAR. Viridian Therapeutics, Inc.\DE's 13F Pro composite quality score has ranged between 26 and 31 since 2026, currently 30.5 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Viridian Therapeutics, Inc.DE

Quirks, history, and lore behind VRDN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Colorado · focused on serious rare diseases.
2
The Numbers
Like most clinical-stage biotechs, it runs on investor capital rather than product revenue, with annual operating losses in the hundreds of millions of dollars as it funds its pipeline.
3
The History
Founded in the 2010s, the company was built around targeting the IGF-1 receptor pathway — a molecular lever implicated in thyroid eye disease and other conditions.
4
The Secret
Its lead program targets thyroid eye disease (TED), a disfiguring and painful autoimmune condition with a limited number of approved treatments — making it a hotly contested therapeutic space.
5
The Lore
The company's name is a nod to the color green — evoking growth and life — fitting for a biotech betting big on monoclonal antibodies that block a single receptor to quiet an overactive immune attack on the eye socket.
6
The Giveaway
Ticker VRDN, named after the Latin for green, this Boulder biotech is racing its anti-IGF-1R antibody against Amgen's tepezza in the thyroid eye disease market.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$141.0K

Net Income

Q1 2026

$-104.9M

Free Cash Flow

Q1 2026

$-119.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+23359.9% YoY

$70.8MFY 2025

FY22 $1.8MFY23 $314.0KFY24 $302.0KFY25 $70.8M

Net Income

-26.9% YoY

$-342.6MFY 2025

FY22 $-129.9MFY23 $-237.7MFY24 $-269.9MFY25 $-342.6M

Operating Income

-21.5% YoY

$-363.4MFY 2025

FY22 $-134.3MFY23 $-254.4MFY24 $-299.0MFY25 $-363.4M

EPS (Diluted)

—FY 2025

FY22 $-4.05FY23 $-5.31FY24 —FY25 —

Total Assets

+21.1% YoY

$899.4MFY 2025

FY22 $435.1MFY23 $490.4MFY24 $742.4MFY25 $899.4M

Total Debt

—FY 2025

FY22 $4.6MFY23 $20.2MFY24 $20.6MFY25 —

Op. Cash Flow

-19.0% YoY

$-276.4MFY 2025

FY22 $-93.8MFY23 $-184.2MFY24 $-232.3MFY25 $-276.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$70.8M +23359.9%	$302.0K -3.8%	$314.0K -82.3%	$1.8M -40.2%	$3.0M +182.2%	$1.1M
Net Income	$-342.6M -26.9%	$-269.9M -13.6%	$-237.7M -83.0%	$-129.9M -63.6%	$-79.4M +28.3%	$-110.7M
Operating Income	$-363.4M -21.5%	$-299.0M -17.5%	$-254.4M -89.5%	$-134.3M -68.5%	$-79.7M +27.8%	$-110.4M
EPS (Diluted)	—	—	$-5.31 -31.1%	$-4.05 +39.2%	$-6.66 +78.6%	$-31.13
Total Assets	$899.4M +21.1%	$742.4M +51.4%	$490.4M +12.7%	$435.1M +113.6%	$203.7M +55.2%	$131.3M
Total Debt	—	$20.6M +1.9%	$20.2M +335.0%	$4.6M	$0.00	—
Operating Cash Flow	$-276.4M -19.0%	$-232.3M -26.1%	$-184.2M -96.3%	$-93.8M -71.9%	$-54.6M -83.3%	$-29.8M

AI Insight: VRDN Financial Trends

Viridian remains pre-commercial with accelerating cash burn — a single $71M revenue quarter in Q3 2025 aside, losses are widening toward $120M/quarter.

• Operating losses deepened from -$72M in Q2 2024 to -$123M in Q4 2025, reflecting sustained R&D spend with no recurring revenue.

• Q3 2025 showed an isolated $71M revenue event that cut net loss to -$35M, but Q4 2025 and Q1 2026 reverted to zero revenue.

• Equity rose from $529M in Q2 2024 to $722M in Q4 2025 — likely via equity raises — but has since declined to $636M in Q1 2026.

• Operating cash outflow hit -$120M in Q1 2026, the worst single quarter in the dataset, signaling accelerating cash consumption.

⚠ Equity dropped $86M quarter-over-quarter in Q1 2026; continued drawdown without new capital raises threatens runway.

⚠ The $71M Q3 2025 revenue spike warrants clarification — whether milestone, licensing, or product — as recurrence is not yet evident.

⚠ Total debt held flat at $21M through Q2 2025 but is unreported in Q4 2025 and Q1 2026 — debt structure needs monitoring.

AI Insight: VRDN Ratio Trends

Return metrics have deteriorated sharply into 2026, with ROIC worsening to -73.1% in Q1 2026 from a Q3 2024 trough recovery — signaling mounting capital inefficiency.

• ROIC deteriorated from -45.9% in Q3 2024 to -73.1% in Q1 2026, reversing a brief mid-2024 improvement.

• ROE swung from -27.5% in Q3 2025 to -66.0% in Q1 2026, suggesting Q3 2025 was an outlier, not a turning point.

• D/E remains minimal at 0.03–0.04 across all reported quarters, indicating the company is not leveraged with debt.

⚠ ROA dropped to -53.2% in Q1 2026 from -24.0% in Q3 2025 — asset base is generating increasingly deep losses.

⚠ OpMargin and NPM data are nearly entirely absent; Q3 2025 single-quarter reads of -56.7% and -49.0% warrant monitoring for consistency.

Get alerted when VRDN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Viridian Therapeutics, Inc.\DE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VRDN

FMR LLC
$300.8M15,379,377 sh
BlackRock, Inc.
$153.2M7,831,475 sh
Bellevue Group AG
$131.6M6,726,144 sh
STATE STREET CORP
$91.4M4,672,885 sh
VANGUARD CAPITAL MANAGEMENT LLC
$81.5M4,167,201 sh
Fairmount Funds Management LLC
$76.6M3,914,458 sh
VR Adviser, LLC
$75.9M3,882,709 sh
Paradigm Biocapital Advisors LP
$61.6M3,148,893 sh
WELLINGTON MANAGEMENT GROUP LLP
$60.2M3,078,554 sh
Kynam Capital Management, LP
$45.8M2,341,652 sh

Fund	Value	Shares
FMR LLC	$300.8M	15,379,377
BlackRock, Inc.	$153.2M	7,831,475
Bellevue Group AG	$131.6M	6,726,144
STATE STREET CORP	$91.4M	4,672,885
VANGUARD CAPITAL MANAGEMENT LLC	$81.5M	4,167,201
Fairmount Funds Management LLC	$76.6M	3,914,458
VR Adviser, LLC	$75.9M	3,882,709
Paradigm Biocapital Advisors LP	$61.6M	3,148,893
WELLINGTON MANAGEMENT GROUP LLP	$60.2M	3,078,554
Kynam Capital Management, LP	$45.8M	2,341,652

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VRDN on your watchlist

Track score changes the day Viridian Therapeutics, Inc.\DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VRDN a good stock to buy?

13F Pro's AI-powered analysis of Viridian Therapeutics, Inc.\DE (VRDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRDN are available on the VRDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VRDN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viridian Therapeutics, Inc.\DE's investment landscape.